Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L0BX
|
||||
| Former ID |
DNC008647
|
||||
| Drug Name |
ICARITIN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Phase 2 | [524499] | ||
| Formula |
C21H20O6
|
||||
| Canonical SMILES |
CC(=CCC1=C(C=C(C2=C1OC(=C(C2=O)O)C3=CC=C(C=C3)OC)O)O)C
|
||||
| InChI |
1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
|
||||
| InChIKey |
TUUXBSASAQJECY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Modulator | ||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||